Ginel-Mendoza Leovigildo, Hidalgo-Natera Alfonso, Reina-Gonzalez Rocío, Poyato-Ramos Rafael, Morales-Naranjo Juana, Lupiañez-Pérez Inmaculada, Baca-Osorio Antonio, Gutiérrez-Jansen Miguel, Fernández-Lara María Paz, Lozano-Noriega Diego, Salgado-Carvallo Ulises, Bandera-García Cristina, Navarro-Moya Francisco Javier
Centro de Salud Ciudad Jardín, Distrito Sanitario Málaga-Guadalhorce, C/ Sancho Miranda 9, 29014, Málaga, Spain.
Andalusian Health Service, District of Málaga-Guadalhorce, Málaga, Spain.
Trials. 2021 Jan 11;22(1):45. doi: 10.1186/s13063-020-04972-1.
Oral anticoagulant drugs represent an essential tool in the prevention of thromboembolic events. The ones in widespread use are vitamin K antagonists, whose plasma level is monitored by measuring prothrombin time using the international normalized ratio. If its values are out of the recommended range, the patient will have a higher risk of suffering from thromboembolic or hemorrhagic complications. Previous research has shown that approximately 33% of patients keep having values at an inappropriate level. The purpose of the proposed study is to improve the international normalized ratio control results by a joint didactic intervention based on the Junta de Andalucía School for Patients method that will be implemented by anticoagulated patients themselves.
A randomized controlled trial will be undertaken at primary care centers from one healthcare area in Málaga (Andalusia, Spain).
patients participating in an oral anticoagulant therapy program of vitamin K antagonists. First step: identification of patients in the oral anticoagulation therapy program with international normalized ratio control of the therapeutic level at 65% or less over total time. Second step: patients with international normalized ratio (INR) control figures under 2 or above 3 will be assigned to two different groups: Group 1 or joint intervention group: patients will be instructed in the joint didactic "from peer to peer," by a previously trained and expert anticoagulant patient. Group 2 or control group: the control group will receive the usual clinical practice. They will be evaluated by nurses about once a month, except for cases in which their INR figures are under 2 or above 3, and those patients will be evaluated more frequently. A total of 312 individuals will be required (156 in each group) to detect differences in INR figures equal to or higher than 15% between the groups.
time on therapeutic levels before and after the intervention; sociodemographic variables; vital signs; the existence of cardiovascular risk factors or accompanying diseases in the clinical records; laboratory test including complete blood counts, bleeding time, and prothrombin time or partial thromboplastin time; and blood chemistry, other prescribed drugs, and social support. A quasi-experimental analytic study with before-after statistical analysis of the intervention will be conducted. Linear regression models will be applied for the main variable results (international normalized ratio value, time on therapeutic level) inputting sociodemographic variables, accompanying diseases, and social support.
ClinicalTrials.gov NCT03647254 . Registered on 27 August 2018.
口服抗凝药物是预防血栓栓塞事件的重要工具。目前广泛使用的是维生素K拮抗剂,其血浆水平通过使用国际标准化比值测量凝血酶原时间来监测。如果其值超出推荐范围,患者发生血栓栓塞或出血并发症的风险将会更高。先前的研究表明,约33%的患者其值持续处于不适当水平。本拟开展研究的目的是通过基于安达卢西亚患者学校方法的联合教学干预来改善国际标准化比值的控制结果,该干预将由接受抗凝治疗的患者自行实施。
将在西班牙安达卢西亚马拉加市一个医疗区域的初级保健中心进行一项随机对照试验。
参与维生素K拮抗剂口服抗凝治疗项目的患者。第一步:确定在口服抗凝治疗项目中,国际标准化比值在治疗水平的总时间控制率为65%或更低的患者。第二步:国际标准化比值(INR)控制数值低于2或高于3的患者将被分配到两个不同的组:第1组或联合干预组:患者将由一名先前接受过培训的专业抗凝患者进行“ peer to peer”联合教学指导。第2组或对照组:对照组将接受常规临床治疗。除了INR数值低于2或高于3的情况外,护士将大约每月对他们进行一次评估,而这些患者将接受更频繁的评估。总共需要312名个体(每组156名)来检测两组之间INR数值差异等于或高于15%的情况。
干预前后处于治疗水平的时间;社会人口统计学变量;生命体征;临床记录中是否存在心血管危险因素或伴随疾病;实验室检查,包括全血细胞计数、出血时间、凝血酶原时间或部分凝血活酶时间;以及血液化学、其他处方药和社会支持。将进行一项干预前后统计分析的准实验性分析研究。将应用线性回归模型来分析主要变量结果(国际标准化比值数值、处于治疗水平的时间),输入社会人口统计学变量、伴随疾病和社会支持。
ClinicalTrials.gov NCT03647254。于2018年8月27日注册。